ISSN 2063-5346

BIOCHEMICAL APPROACHES TO DRUG DISCOVERY AND DEVELOPMENT

Nakka Venkata Naga Jyothi [a], Sunita Patnaik [b], Dr. Vamseedhar Annam [c], M.Krishnaveni [d]

Article History: Received: 10.05.2023 Revised: 15.06.2023 Accepted: 28. 06.2023

Abstract

Biochemical approaches play a crucial role in the process of drug discovery and development. These approaches encompass a wide range of techniques and methodologies that enable researchers to identify and optimize potential drug candidates with high efficacy and minimal side effects. This abstract provides an overview of the various biochemical approaches employed in drug discovery and development, including target identification and validation, high-throughput screening, structure-activity relationship studies, lead optimization, and preclinical testing. Additionally, it highlights the integration of computational tools and technologies in guiding and enhancing biochemical approaches. The utilization of these techniques not only accelerates the drug discovery process but also improves the chances of successful translation from bench to bedside. Overall, biochemical approaches form the foundation of modern drug discovery, enabling the development of innovative therapies for various diseases and medical conditions.

***Keywords**: Biochemical approaches, Drug discovery, Drug development, Target identification, Target validation, High-throughput screening, Structure-activity relationship, Lead optimization, Preclinical testing, Computational tools, Translational medicine.*

[a] Assistant Professor, department of Pharmaceutics, KL College of Pharmacy, Koneru Lakshmaiah Education Foundation deemed to be University, Green fields, Vaddeswaram, Guntur District, Andhra Pradesh, India, pin 522502.

[b] Assistant Professor, Roland institute of pharmaceutical sciences, Berhampur

[C] Professor, Department Of Pathology, Rajarajeswari Medical College and Hospital, Kambipura, Mysore Road, Bangalore - 560074.

[d] Assistant Professor in Biochemistry, Nadar Saraswathi College of Arts & Science, Theni, Tamilnadu, India.

Corresponding Author: nvn.jyothi567@gmail.com

Co-author: sunita.patnaik01@gmail.com, vamseedhar_a@yahoo.com, venibio87@gmail.com

Introduction

The process of drug discovery and development involves the identification and development of new therapeutic agents to treat various diseases and medical conditions. It is a complex and resource-intensive process that requires a multidisciplinary approach, with biochemical techniques playing a crucial role from the early stages of drug development. Biochemical approaches are essential in drug discovery because they provide valuable insights into the molecular mechanisms underlying diseases and help identify potential targets for intervention. These approaches involve the study of biological molecules, such as proteins, enzymes, receptors, and nucleic acids, and their interactions with small molecules or drug candidates.

Biochemical techniques, such as enzymatic assays, receptor binding assays, and cell-based assays, allow researchers to assess the activity and function of potential drug targets. By understanding the biochemical pathways and interactions involved in disease processes, researchers can design more effective and specific drug interventions. Moreover, biochemical approaches are integrated with other disciplines, such as medicinal chemistry, pharmacology, and computational biology, to optimize drug candidates and enhance their therapeutic potential. The collaboration between these disciplines allows for a comprehensive understanding of the drug's mechanisms of action, pharmacokinetics, and safety profiles [1].

Target Identification and Validation

One of the primary goals of drug discovery is to identify suitable targets for intervention. Biochemical approaches play a crucial role in this process by enabling researchers to identify and validate disease-associated targets. These approaches involve the use of biochemical assays to study the activity, expression, and regulation of potential targets in disease-relevant tissues or models. Target identification often starts with the analysis of disease pathways and the identification of key molecules involved. Biochemical techniques, such as proteomics and metabolomics, help in identifying differentially expressed proteins or metabolites associated with the disease. These biomarkers can serve as potential targets or indicators of therapeutic response.

Once potential targets are identified, biochemical assays are employed to validate their relevance and drug ability. These assays assess the interaction between the target molecule and potential drug candidates, providing insights into binding affinities, enzymatic activity modulation, and downstream effects on disease-related pathways. The integration of biochemical approaches with genomics and bioinformatics allows for a systematic analysis of genetic and molecular data to prioritize and validate potential drug targets. This interdisciplinary approach enhances the success rate of target identification and validation, leading to more efficient drug discovery [2].

High-Throughput Screening (HTS)

High-throughput screening is a critical stage in drug discovery that allows for the rapid screening of large compound libraries to identify potential hits or lead compounds. Biochemical approaches, particularly assay development and optimization, are integral to the success of HTS campaigns.

Biochemical assays used in HTS are designed to measure the interaction or modulation of target molecules by small molecules or drug candidates. These assays can be enzymatic, receptor-based, or cell-based, depending on the nature of the target and the disease being studied. Assay development involves designing robust and sensitive biochemical assays that can be automated and scaled for high-throughput screening. This includes optimizing assay conditions, selecting appropriate detection methods, and validating assay performance metrics such as sensitivity, specificity, and reproducibility.

During HTS, large compound libraries are screened against the target of interest using the biochemical assay. Hits, or compounds showing activity or affinity towards the target, are identified and further validated through secondary assays. These hits serve as starting points for lead optimization and subsequent drug development stages. High-throughput screening, enabled by biochemical approaches, accelerates the drug discovery process by quickly identifying potential lead compounds from vast compound libraries, providing a solid foundation for subsequent optimization steps [3].

Structure-Activity Relationship (SAR) Studies

Structure-activity relationship (SAR) studies aim to understand the relationship between the chemical structure of a compound and its biological activity. Biochemical approaches, in conjunction with medicinal chemistry, play a pivotal.

Target Identification and Validation

Target identification and validation are critical steps in the drug discovery process, and biochemical assays play a vital role in these stages. The following are key aspects of target identification and validation using biochemical approaches

Identification of disease targets using biochemical assays

Biochemical assays are employed to identify disease-relevant targets involved in specific biological pathways or disease processes. These assays assess the activity, expression, or regulation of potential targets in disease-relevant tissues, cells, or model systems. For example, enzyme assays can be used to identify and quantify enzymatic activities associated with disease progression or aberrant signalling pathways.

Validation of target suitability and drug ability

Once potential targets are identified, it is crucial to validate their suitability for drug intervention. Biochemical assays are used to validate the target's role in disease pathology and its potential as a therapeutic target. These assays provide insights into the target's functional significance, including its role in signalling cascades, protein-protein interactions, or enzymatic activity modulation. By understanding the target's biochemical characteristics, researchers can assess its suitability for drug development and the likelihood of achieving desired therapeutic outcomes [4].

Biomarker discovery for personalized medicine: Biochemical approaches also contribute to biomarker discovery, which has profound implications for personalized medicine. Biomarkers are measurable indicators that reflect normal or pathological processes, and they can be used to predict, diagnose, or monitor disease progression and therapeutic response. Biochemical assays, such as proteomics and metabolomics, enable the identification and quantification of disease-specific biomarkers. These biomarkers can aid in patient stratification, allowing for the development of targeted therapies based on individual characteristics and disease profiles.

Overall, biochemical assays are integral to the identification and validation of disease targets in drug discovery. They provide essential information about the target's function, drug ability, and potential as a therapeutic intervention. Furthermore, biochemical approaches contribute to the discovery of biomarkers, enabling personalized medicine approaches for improved patient care.

High-Throughput Screening (HTS)

High-throughput screening (HTS) is a pivotal stage in drug discovery that enables the rapid screening of large compound libraries to identify potential hits or lead compounds. The following aspects highlight the principles and methodologies of HTS, as well as the crucial steps involved:

Principles and methodologies of HTS

HTS is based on the principle of testing a large number of compounds against a target of interest in a short period. The goal is to identify compounds that exhibit activity or affinity towards the target, providing starting points for further optimization. HTS campaigns are typically conducted using automated systems and miniaturized assays to achieve high throughput and efficiency [5].

Assay development for HTS campaigns

A critical step in HTS is the development of robust and sensitive biochemical assays that can be adapted for high-throughput screening. These assays should be reliable, reproducible, and amenable to automation. Assay development involves optimizing experimental conditions, such as pH, temperature, substrate concentrations, and reaction time, to ensure optimal assay performance. Additionally, detection methods, such as fluorescence, luminescence, or absorbance, are selected to measure the activity or interaction of the target and compounds.

Screening libraries and compound collections

HTS requires access to diverse compound libraries or collections. These libraries may consist of synthetic small molecules, natural product extracts, or focused libraries designed based on specific target characteristics. Screening libraries are typically comprised of thousands to millions of compounds. The selection of the library depends on the target and the disease being investigated. The compound collections are stored in plate-based formats to enable rapid handling and screening [6].

Hit identification and confirmation

During HTS, compounds that exhibit activity or affinity towards the target are identified as hits. These hits require further validation and confirmation to ensure their reliability. Secondary assays are performed to confirm the activity and specificity of the hits. These assays may involve orthogonal techniques or alternative biochemical assays to confirm the initial screening results. Further characterization, such as determining the dose-response relationship or evaluating selectivity against other targets, is conducted to prioritize the most promising hit compounds for subsequent optimization and lead development. HTS is a crucial step in the drug discovery process, and its success depends on robust assay development, access to diverse compound libraries, and accurate hit identification and confirmation. The utilization of high-throughput screening techniques accelerates the identification of potential lead compounds and expedites the drug discovery process [7].

Structure-Activity Relationship (SAR) Studies

Structure-Activity Relationship (SAR) studies are an essential component of drug discovery and development. These studies aim to establish the relationship between the chemical structure of a compound and its biological activity. The following points highlight key aspects of SAR studies and their significance in the drug development process:

Rational drug design based on structural information

SAR studies provide insights into how the structural features of a compound contribute to its activity, potency, selectivity, and other pharmacological properties. By understanding the structural requirements for target binding and activity, researchers can design and modify compounds rationally to optimize their pharmacological profile. Structural information, such as X-ray crystallography or computational modelling, helps in visualizing the interactions between a compound and its target, guiding the design of new analogues or derivatives with improved activity.

Structure-based drug optimization

SAR studies allow for the optimization of lead compounds through structure-based drug design. By analysing the SAR data, researchers can identify key molecular interactions, binding motifs, and regions of the compound that contribute to its activity or selectivity. This information can guide the modification or optimization of the compound's structure to enhance its potency, improve pharmacokinetic properties, or reduce toxicity. Rational modifications may include altering functional groups, stereochemistry, or substituents based on SAR insights [8].

II. COMPUTATIONAL TOOLS FOR SAR ANALYSIS

Computational tools and techniques play a crucial role in SAR analysis. They aid in the prediction and modelling of compound-target interactions, as well as in the analysis of large datasets. Molecular modelling, molecular dynamics simulations, and docking studies are commonly used computational methods to assess the binding affinity, binding mode, and structural interactions between a compound and its target. These tools allow researchers to explore the SAR space more efficiently, prioritize compound design strategies, and reduce the time and cost associated with experimental screening.

SAR studies help in identifying structure-activity relationships and optimizing lead compounds for improved therapeutic potential. By systematically exploring the SAR space, researchers can design and develop compounds with enhanced potency, selectivity, and pharmacological properties. The integration of computational tools with experimental SAR data enhances the efficiency and success rate of drug discovery, facilitating the selection and optimization of potential drug candidates [9].

Lead Optimization

Lead optimization is a crucial phase in drug discovery that focuses on refining and optimizing lead compounds identified during the early stages. This phase aims to improve the potency, selectivity, pharmacokinetic properties, and safety profile of lead compounds to increase their chances of successful development into drug candidates. The following points highlight key aspects of lead optimization:

Medicinal chemistry approaches for lead optimization

Medicinal chemistry plays a central role in lead optimization. It involves the design, synthesis, and modification of lead compounds to improve their desired properties. Medicinal chemists utilize SAR data, structural information, and knowledge of the target and disease biology to guide the rational modification of lead compounds. This process often involves the synthesis of analogs or derivatives with subtle structural changes to explore the SAR space and identify compounds with improved activity or selectivity.

Structure-activity relationship (SAR) studies for lead compounds

SAR studies continue to be an integral part of lead optimization. By systematically evaluating the relationship between the structural modifications of lead compounds and their biological activity, researchers can optimize their pharmacological properties. SAR studies help identify critical structural features, functional groups, and regions that impact activity, and guide the synthesis of compound analogues with desired properties. These studies often involve iterative cycles of synthesis, testing, and SAR analysis to fine-tune the lead compounds [10].

Optimization of drug-like properties (ADME-Tox)

Lead optimization also focuses on optimizing drug-like properties to ensure a compound's efficacy, safety, and pharmacokinetic profile. The absorption, distribution, metabolism, excretion, and toxicity (ADME-Tox) properties of lead compounds are assessed and improved during this stage. Medicinal chemists aim to enhance a compound's oral bioavailability, metabolic stability, solubility, and permeability. Additionally, they aim to minimize toxicity risks by reducing off-target effects and optimizing the compound's safety profile through modifications guided by SAR and ADME-Tox studies.

Lead optimization involves a multidisciplinary approach that integrates medicinal chemistry, SAR studies, and ADME-Tox assessments. It aims to refine and optimize lead compounds to maximize their therapeutic potential while minimizing undesirable effects. By systematically improving potency, selectivity, and pharmacokinetic properties, lead optimization increases the likelihood of identifying drug candidates with optimal efficacy and safety profiles for further development.

III. PRECLINICAL TESTING

Preclinical testing is a crucial stage in the drug development process that involves evaluating the safety, efficacy, and pharmacological properties of potential drug candidates before they advance to clinical trials. The following points highlight key aspects of preclinical testing:

In vitro and in vivo evaluation of drug candidates

During preclinical testing, drug candidates undergo extensive evaluation using both in vitro and in vivo models. In vitro assays involve testing the compounds in controlled laboratory settings using cell-based systems, tissue cultures, or isolated enzymes. These assays provide insights into the compound's mechanisms of action, target engagement, and potential efficacy.

In vivo studies involve testing the drug candidates in animal models, which closely mimic human physiology and disease conditions. These studies assess various parameters, including pharmacokinetics (absorption, distribution, metabolism, and excretion), pharmacodynamics (drug-target interactions, efficacy), and toxicology (safety profile) [11].

Biochemical assays for pharmacokinetic and pharmacodynamics studies

Biochemical assays play a crucial role in assessing the pharmacokinetic and pharmacodynamics properties of drug candidates during preclinical testing. Pharmacokinetic studies involve measuring the compound's absorption, distribution, metabolism, and excretion in animals, which provide insights into its bioavailability, half-life, and tissue distribution. Biochemical assays, such as liquid chromatography-mass spectrometry (LC-MS), enable the quantification and analysis of drug concentrations in biological samples.

Pharmacodynamics studies focus on understanding how the drug candidate interacts with its target and affects relevant biological pathways or processes. Biochemical assays are used to assess target engagement, modulation of enzymatic activity, receptor binding affinity, or downstream signalling effects. These assays provide valuable information about the compound's mechanism of action, efficacy, and potential side effects [12].

Toxicity testing and safety assessment: Assessing the safety profile of drug candidates is a critical aspect of preclinical testing. Toxicity testing involves evaluating the potential adverse effects of the compound on various organs, systems, and functions. Biochemical assays, such as liver function tests, renal function tests, and haematological analyses, help monitor biomarkers and detect any signs of toxicity or organ damage.

Additionally, safety assessment includes evaluating the compound's potential for genotoxicity, mutagenicity, and carcinogenicity. These assessments utilize biochemical assays to detect DNA damage, chromosomal aberrations, or other genotoxic effects. Preclinical testing aims to provide comprehensive data on the safety, efficacy, and pharmacological properties of drug candidates. The integration of biochemical assays, both in vitro and in vivo, enables the assessment of pharmacokinetics, pharmacodynamics, and toxicity, facilitating informed decision-making regarding the progression of potential drug candidates to clinical trials.

IV.INTEGRATION OF COMPUTATIONAL TOOLS

The integration of computational tools has revolutionized the field of drug discovery and development, offering powerful approaches to enhance efficiency and success rates. The following points highlight key computational tools and their integration into the drug discovery process:

Molecular modelling and virtual screening

Molecular modelling techniques, such as molecular docking and ligand-based virtual screening, are employed to predict and analyse the interactions between drug candidates and their target proteins. These methods utilize three-dimensional structural information of the target and compounds to evaluate binding affinities and identify potential lead compounds. Molecular modelling helps in prioritizing compounds for experimental testing, reducing the time and cost associated with synthesis and screening.

Molecular dynamics simulations and binding affinity predictions

Molecular dynamics (MD) simulations are

computational techniques that simulate the motion and behaviour of atoms and molecules over time. MD simulations provide insights into the dynamic behaviour of drug-target complexes, elucidating their stability, conformational changes, and binding interactions. These simulations aid in predicting binding affinities, estimating binding free energies, and guiding the optimization of lead compounds. MD simulations can also help in understanding the impact of mutations or structural variations on drug-target interactions [13].

Bioinformatics and data mining approaches

Bioinformatics and data mining approaches are utilized to extract valuable information from large biological datasets. These approaches involve the analysis and integration of various data types, including genomic data, proteomic data, and chemical databases. Bioinformatics tools and algorithms help identify potential drug targets, discover new therapeutic targets, predict off-target effects, and facilitate the exploration of biological pathways and networks. Data mining techniques assist in the identification of patterns, correlations, and relationships within complex datasets, aiding in the identification of novel drug candidates or repurposing existing drugs for new indications.

The integration of computational tools enhances the efficiency and success rates of the drug discovery process. By utilizing molecular modelling, virtual screening, molecular dynamics simulations, bioinformatics, and data mining approaches, researchers can accelerate target identification, lead optimization, and toxicity prediction. The computational tools facilitate the rational design of compounds, aid in the interpretation of experimental data, and reduce the time and cost associated with experimental screening. The integration of computational and experimental approaches forms a powerful synergy, enabling researchers to make informed decisions and improve the overall efficiency of drug discovery and development [14].

Translational Medicine and Clinical Trials

Translational medicine bridges the gap between preclinical research and clinical development, facilitating the translation of promising discoveries into effective therapies for patients. Clinical trials are a crucial component of translational medicine, where the safety, efficacy, and optimal use of drug candidates are evaluated in human subjects. The following points highlight key aspects of translational medicine and clinical trials:

Transition from preclinical to clinical development

The transition from preclinical to clinical development involves several steps to ensure the safe and effective use of drug candidates in humans. Preclinical data, including in vitro and in vivo studies, are carefully analysed to establish a rationale for clinical trials. Pharmacokinetics, pharmacodynamics, and toxicology data from preclinical studies inform the design of the initial clinical trials. Additionally, regulatory considerations and ethical approvals are obtained before proceeding with clinical trials.

Biomarker-driven clinical trials

Biomarkers play a crucial role in clinical trials, aiding in patient selection, treatment response monitoring, and assessing drug safety. Biomarkers can be biochemical, genetic, or molecular characteristics that indicate the presence of a particular disease, predict treatment outcomes, or guide patient stratification. Biochemical approaches, such as biomarker discovery through proteomics or metabolomics, enable the identification and validation of relevant biomarkers. Biomarker-driven clinical trials help in selecting patients who are more likely to benefit from the treatment, improving the chances of successful outcomes.

Biochemical approaches in patient selection and stratification

Biochemical approaches contribute to patient selection and stratification in clinical trials. Biomarkers can be utilized to identify patient subgroups that are more likely to respond to the treatment or to predict potential adverse effects. By analysing biochemical profiles, genetic variations, or molecular signatures, researchers can identify patient characteristics that influence treatment response, enabling personalized medicine approaches. Biochemical assays are also employed to monitor treatment efficacy and assess the pharmacokinetics and pharmacodynamics of the drug in individual patients [15].

Translational medicine and clinical trials aim to bridge the gap between preclinical research and the development of safe and effective therapies for patients. The integration of biochemical approaches, including biomarker-driven clinical trials and patient stratification based on biochemical profiles, enhances the success of clinical trials by optimizing patient selection, treatment response monitoring, and overall therapeutic outcomes. Translational medicine facilitates the translation of preclinical discoveries into clinical practice, ultimately improving patient care and advancing the field of medicine.

V. EMERGING TRENDS AND FUTURE PERSPECTIVES

The field of drug discovery and development is constantly evolving, driven by advancements in biochemical techniques, gene editing technologies, and the integration of artificial intelligence (AI) and machine learning. These emerging trends hold great promise for enhancing the efficiency and success rates of drug discovery. The following points highlight these trends and their future perspectives:

Advancements in biochemical techniques (e.g., proteomics, metabolomics)

Technological advancements in biochemical techniques, such as proteomics and metabolomics, offer unprecedented opportunities for understanding the complex biological processes underlying diseases and drug responses. Proteomics enables the comprehensive analysis of proteins, theirpost-translational modifications, and interactions, providing insights into disease mechanisms and identifying potential drug targets. Metabolomics allows for the profiling of small molecules involved in cellular metabolism, facilitating the discovery of disease biomarkers and understanding drug metabolism. Continued advancements in these techniques, including higher throughput and improved sensitivity, will enable deeper insights into disease biology and personalized medicine [16].

Application of CRISPR/Cas9 and gene editing technologies

The revolutionary CRISPR/Cas9 gene editing technology has transformed the field of molecular biology and holds significant potential for drug discovery. CRISPR/Cas9 allows precise editing of the genome, enabling the investigation of gene functions, disease mechanisms, and the development of cell and animal models for drug screening. Gene editing technologies offer the possibility of correcting disease-causing genetic mutations, opening new avenues for developing targeted therapies. As these technologies continue to evolve, their application in drug discovery and development is expected to expand, leading to more precise and personalized treatment approaches.

Integration of artificial intelligence and machine learning in drug discovery

Artificial intelligence (AI) and machine learning (ML) are revolutionizing drug discovery by enabling the analysis of large-scale data, prediction of compound properties, and optimization of lead compounds. AI and ML algorithms can analyze vast amounts of data, including genomic information, chemical databases, and clinical data, to identify patterns and predict compound-target interactions. These technologies aid in virtual screening, de novo drug design, and the identification of potential drug candidates. The integration of AI and ML in drug discovery accelerates the identification of lead compounds, reduces the costs associated with experimental screening, and enhances the overall efficiency of the process.

The future of drug discovery and development holds tremendous potential with these emerging trends. Advancements in biochemical techniques, gene editing technologies, and AI/ML are expected to further drive innovation and accelerate the discovery of novel therapeutics. The integration of these approaches will enable a more comprehensive understanding of diseases, facilitate the development of personalized medicines, and pave the way for more efficient and targeted drug discovery pipelines [17].

VI. CONCLUSION

Biochemical approaches play a crucial role in the process of drug discovery and development, offering valuable tools and insights for identifying and optimizing potential therapeutics. Throughout this review, we have explored various aspects of biochemical approaches in drug discovery and development. Here, we summarize their key contributions and discuss potential future directions and challenges in the field.

Biochemical approaches, such as target identification and validation, high-throughput screening, structure-activity relationship studies, lead optimization, preclinical testing, and the integration of computational tools, have significantly advanced the drug discovery process. These approaches provide a solid foundation for rational drug design, lead optimization, and safety assessment. They enable the identification and validation of disease targets, screening of large compound libraries, optimization of lead compounds based on their structure-activity relationships, and evaluation of pharmacokinetics, pharmacodynamics, and toxicity. Moreover, the integration of computational tools, including molecular modeling, virtual screening, molecular dynamics simulations, and bioinformatics, enhances efficiency, accuracy, and prediction capabilities in drug discovery [18].

The future of biochemical approaches in drug discovery and development holds great promise. Advancements in proteomics, metabolomics, CRISPR/Cas9 gene editing, and artificial intelligence/machine learning are expected to drive further innovation. These technologies will enable a deeper understanding of disease mechanisms, discovery of novel therapeutic targets, and more efficient and personalized drug development.

However, along with these opportunities, challenges persist. One of the key challenges is the complex nature of diseases and the need for a better understanding of their underlying mechanisms. Many diseases are multifactorial, and achieving optimal therapeutic outcomes requires a comprehensive understanding of the intricate interplay of biological pathways. Additionally, the translation of promising preclinical findings into clinically successful therapies remains a significant challenge. Bridging the gap between preclinical and clinical stages, improving the predictive power of preclinical models, and addressing issues of drug efficacy, safety, and patient stratification are ongoing challenges that need to be addressed [19].

In conclusion, biochemical approaches have revolutionized the field of drug discovery and development, significantly improving the efficiency and success rates of identifying novel therapeutics. The integration of biochemical techniques, computational tools, and emerging technologies promises to further accelerate the discovery of effective and personalized therapies. Despite the challenges, the future of biochemical approaches in drug discovery is bright, with the potential to transform the landscape of medicine and improve patient outcomes [20].

References

[1] Hopkins AL, Groom CR. The druggable genome. Nat Rev Drug Discov. 2002;1(9):727-730.
[2] Drews J. Drug discovery: a historical perspective. Science. 2000;287(5460):1960-1964.
[3] Workman P, Collins I. Probing the probes: fitness factors for small molecule tools. Chem Biol. 2010;17(6):561-577.
[4] Lazo JS, Brady LS, Dingledine R, et al. NIH molecular libraries initiative. Science. 2007;316(5827):1401-1402.
[5] Hajduk PJ, Huth JR, Tse C. Predicting protein druggability. Drug Discov Today. 2005;10(23-24):1675-1682.
[6] Liebler DC, Zimmerman LJ. Targeted quantitation of proteins by mass spectrometry. Biochemistry. 2013;52(22):3797-3806.

[7] Madsen U, Brimacombe KR. High-throughput screening: advances in assay technologies. Curr Opin Chem Biol. 2005;9(4):364-371.

[8] Congreve M, Carr R, Murray C, Jhoti H. A 'rule of three' for fragment-based lead discovery? Drug Discov Today. 2003;8(19):876-877.

[9] Shoichet BK. Screening in a spirit haunted world. Drug Discov Today. 2006;11(13-14):607-615.

[10] Sherman W, Day T, Jacobson MP, Friesner RA, Farid R. Novel procedure for modeling ligand/receptor induced fit effects. J Med Chem. 2006;49(2):534-553.

[11] Duan J, Dixon SL, Lowrie JF, Sherman W. Analysis and comparison of 2D fingerprints: insights into database screening performance using eight fingerprint methods. J Mol Graph Model. 2010;29(2):157-170.

[12] Wang R, Gao Y, Lai L. LigBuilder: a multi-purpose program for structure-based drug design. J Mol Model. 2000;6(7-8):498-516.

[13] Bajorath J. Integration of virtual and high-throughput screening. Nat Rev Drug Discov. 2002;1(11):882-894.

[14] Li J, Gramatica P. Computational modeling approaches to receptor-ligand interactions in drug discovery and design. Curr Med Chem. 2010;17(31):3661-3681.

[15] Law V, Knox C, Djoumbou Y, et al. DrugBank 4.0: shedding new light on drug metabolism. Nucleic Acids Res. 2014;42(Database issue):D1091-1097.

[16] Yuan H, Pinto E, Wu H, et al. A high-throughput screening paradigm for discovering small-molecule modulators of protein-protein interaction. Chem Biol. 2010;17(4):348-359.

[17] Gilson MK, Liu T, Baitaluk M, et al. BindingDB in 2015: a public database for medicinal chemistry, computational chemistry and systems pharmacology. Nucleic Acids Res. 2016;44(D1):D1045-1053.

[18] Ekins S, Mestres J, Testa B. In silico pharmacology for drug discovery: applications of molecular docking and virtual screening. Curr Opin Pharmacol. 2007;7(6):586-594.

[19] Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001;46(1-3):3-26.

[20] Anighoro A, Bajorath J, Rastelli G. Polypharmacology: challenges and opportunities in drug discovery. J Med Chem. 2014;57(19):7874-7887.